Provided are bifunctional small molecules of Formula (I): or pharmaceutically acceptable
salts thereof, wherein M rep resents a small organic molecule which binds, covalently or non …

Feb. 19, 2013 (JP)................................. 2013-O29563 Jul. 5, 2013 (JP)................................. 2013-
141246 (57) ABSTRACT The present invention provides a drug containing a com (51) Int …

2014-10-24 Assigned to ONO PHARMACEUTICAL CO., LTD. reassignment ONO
PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE …

US9180127B2 - Type II Raf kinase inhibitors - Google Patents US9180127B2 - Type II Raf
kinase inhibitors - Google Patents Type II Raf kinase inhibitors Download PDF Info Publication …

(51) Int. Cl. Ben-Av et al., Induction of vascular endothelial growth factor CO7D
53/04(2006.01) expression in Synovial fibroblasts by prostaglandin E and A6 IK …

The invention features compounds, pharmaceutical compo sitions and methods for treating
patients who have an EGFR-driven cancer of formula I:(52) Int. Cl. C07D 239/46(2006. 01) …

The present disclosure provides combination therapy of a transcription inhibitor and a
kinase inhibitor. The combination of the transcription inhibitor and the kinase inhibitor may …

First worldwide family litigation filed litigation Critical https://patents. darts-ip. com/? family=
41340562&utm_source= google_patent&utm_medium= platform_link&utm_campaign …

2015-08-17 Assigned to NATIONAL INSTITUTES OF HEALTH (NIH), US DEPT. OF HEALTH
AND HUMAN SERVICES (DHHS), US GOVERNMENT reassignment NATIONAL …

2014-06-27 Assigned to BETH ISRAEL DEACONESS MEDICAL CENTER, INC.
reassignment BETH ISRAEL DEACONESS MEDICAL CENTER, INC. ASSIGNMENT OF …